☆ 3.8 Article

Anti-thymocyte globulin exposure in patients with diffuse cutaneous systemic sclerosis undergoing autologous haematopoietic stem cell transplantation

JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2023)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort

Jose Carlos Jaime-Perez et al.

Summary: Autologous hematopoietic stem cell transplantation (HSCT) without anti-thymocyte globulin (ATG) can be a viable treatment alternative for patients with severe, refractory autoimmune rheumatic diseases (ARDs). This study demonstrated that some patients achieved remission and improved functionality post-HSCT, highlighting the potential benefits of HSCT for selected patients with ARDs. Further research is needed to identify the optimal candidate and conditioning regimen for HSCT when ATG is not available.

CLINICAL RHEUMATOLOGY (2022)

Add to Collection

Article Hematology

Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial

Rick Admiraal et al.

Lancet Haematology (2022)

Add to Collection

Article Hematology

Antithymocyte globulin exposure in CD34 + T-cell-depleted allogeneic hematopoietic cell transplantation

Madhavi Lakkaraja et al.

Summary: The traditional weight-based dosing in rabbit antithymocyte globulin (rATG) treatment leads to variable clearance and higher mortality. A personalized pharmacokinetic-guided rATG dosing strategy can improve patient survival.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party

Joerg Henes et al.

Summary: This study confirms the efficacy and safety of autologous stem cell transplantation in the treatment of severe systemic sclerosis. It also identifies some prognostic factors that can affect treatment outcomes. Careful cardio-pulmonary assessment before transplantation, reduced cyclophosphamide doses, and CD34(+)-cell selection may improve treatment outcomes.

HAEMATOLOGICA (2021)

Add to Collection

Article Immunology

Association of the areas over and under the lymphocyte curve with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation

Shun-ichi Kimura et al.

Summary: The impact of areas over and under the lymphocyte curve (L_AOC vs L_AUC) on cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplantation (HSCT) was compared retrospectively. L_AOC15 and L_AUC15 were identified as independent predictive factors for CMV reactivation, along with advanced age and CMV serostatus, but were not superior to absolute lymphocyte count for prediction accuracy. ALC at day 14 or day 21 showed similar accuracy to L_AOC15 and L_AUC15 for predicting CMV reactivation.

TRANSPLANT INFECTIOUS DISEASE (2021)

Add to Collection

Article Rheumatology

Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience

Alvaro Henrique-Neto et al.

Summary: This study investigated the clinical outcomes of 70 SSc patients who underwent autologous hematopoietic progenitor cell transplantation. The results showed that HSCT can improve skin and interstitial lung involvement, increasing patients' overall survival and progression-free survival rates.

ADVANCES IN RHEUMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol

Julia Spierings et al.

Summary: This study aims to determine the optimal treatment strategy for early diffuse cutaneous systemic sclerosis by comparing upfront autologous hematopoietic stem cell transplantation with immunosuppressive therapy. The primary outcome is event-free survival at 2 years after randomization, with secondary outcomes including serious adverse events, functional status, and health-related quality of life.

BMJ OPEN (2021)

Add to Collection

Review Rheumatology

Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all

J. Spierings et al.

Summary: Systemic sclerosis (SSc) is a rare rheumatic disease characterized by inflammation, vasculopathy, and fibrosis. Interstitial lung disease (ILD) is a common complication and leading cause of death in SSc. Autologous stem cell transplantation (SCT) has been increasingly used in progressive diffuse cutaneous SSc, improving survival and quality of life for patients.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2021)

Add to Collection

Review Oncology

Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation

Linde Dekker et al.

CANCERS (2020)

Add to Collection

Article Rheumatology

CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan

Masahiro Ayano et al.

ARTHRITIS RESEARCH & THERAPY (2019)

Add to Collection

Article Medicine, General & Internal

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

K. M. Sullivan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Rheumatology

Update of EULAR recommendations for the treatment of systemic sclerosis

Otylia Kowal-Bielecka et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Add to Collection

Article Hematology

Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis

Rick Admiraal et al.

LANCET HAEMATOLOGY (2017)

Add to Collection

Article Biophysics

Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation

L. Binkert et al.

BONE MARROW TRANSPLANTATION (2015)

Add to Collection

Article Pharmacology & Pharmacy

Population Pharmacokinetic Modeling of Thymoglobulin (R) in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing

Rick Admiraal et al.

CLINICAL PHARMACOKINETICS (2015)

Add to Collection

Article Medicine, General & Internal

Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis A Randomized Clinical Trial

Jacob M. van Laar et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

Add to Collection

Article Medicine, General & Internal

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

Richard K. Burt et al.

LANCET (2011)

Add to Collection

Review Rheumatology

Incidence and prevalence of systemic sclerosis: A systematic literature review

Helene Chifflot et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2008)

Add to Collection

Review Oncology

Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond

M. Mohty

LEUKEMIA (2007)

Add to Collection

Article Immunology

Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase

Stephanie Gillet-Hladky et al.

TRANSPLANTATION (2006)

Add to Collection

Article Immunology

Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins.

MC Michallet et al.

TRANSPLANTATION (2003)

Add to Collection

Article Immunology

Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells

P Monti et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.